Edobacomab
Edobacomab, codenamed E5, is a mouse monoclonal antibody that was investigated as a possible treatment for sepsis caused by Gram-negative bacterial infections.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | endotoxin |
| Clinical data | |
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  | |
Further reading
- Greenman RL; Schein RM; Martin MA; et al. (August 1991). "A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group". JAMA. 266 (8): 1097–102. doi:10.1001/jama.266.8.1097. PMID 1865542.
- Bone RC; Balk RA; Fein AM; et al. (June 1995). "A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group". Crit. Care Med. 23 (6): 994–1006. doi:10.1097/00003246-199506000-00003. PMID 7774238.
- Angus DC; Birmingham MC; Balk RA; et al. (April 2000). "E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators". JAMA. 283 (13): 1723–30. doi:10.1001/jama.283.13.1723. PMID 10755499.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.